Boehringer and Torrent Pharma to co-market diabetes drugs in India
India’s Torrent Pharmaceuticals (BSE: 500420) has inked a strategic alliance with Germany’s Boehringer Ingelheim to co-market diabetes drugs and fixed-dose combinations in India. The Indian company will co-market empagliflozin, empagliflozin+ metformin and empagliflozin+ linagliptin in India.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor that improves glycemic control in adults with type-2 diabetes. Additionally, it reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
As a result of the drug alliance, India patients will be able to address the dual challenges of diabetes type-2 and heart failure. Approximately 74.2 million adult patients, between 20 and 79 years of age, have diabetes in India as of 2021, according to the International Diabetes Federation. This is expected to increase to almost 125 million patients by 2045.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze